Search Results - "GUIGAY, Joel"

Editorial: Head and neck cancers: recent pathological approaches and new therapeutic guidelines for sino-nasal, thyroid and squamous cell carcinomas by Guigay, Joël

Get full text

Things are changing for head and neck squamous cell carcinomas by Guigay, Joël

Get full text

Molecular genetics of head and neck squamous cell carcinoma by Saada-Bouzid, Esma, Peyrade, Frederic, Guigay, Joël

“…PURPOSE OF REVIEWThe aim of this review is to summarize the current knowledge on the genomic characterization of squamous cell carcinomas of the head and neck…”
Get full text

Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck by Saada-Bouzid, Esma, Peyrade, Frederic, Guigay, Joël

“…PURPOSE OF REVIEWCheckpoint inhibitors (CPI) are revolutionizing the treatment of advanced cancers including recurrent and or metastatic squamous cell…”
Get full text

Advances in nasopharyngeal carcinoma by Guigay, Joël

“…PURPOSE OF REVIEWNasopharyngeal carcinoma prognosis is related to its potential locoregional invasion and metastatic spread. Among prognostic factors, initial…”
Get full text

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial by Machiels, Jean-Pascal H, Prof, Haddad, Robert I, MD, Fayette, Jérôme, MD, Licitra, Lisa F, MD, Tahara, Makoto, MD, Vermorken, Jan B, Prof, Clement, Paul M, Prof, Gauler, Thomas, MD, Cupissol, Didier, MD, Grau, Juan José, MD, Guigay, Joël, Prof, Caponigro, Francesco, MD, de Castro, Gilberto, PhD, de Souza Viana, Luciano, MD, Keilholz, Ulrich, Prof, del Campo, Joseph M, MD, Cong, Xiuyu Julie, PhD, Ehrnrooth, Eva, MD, Cohen, Ezra E W, MD

“…Summary Background Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (HNSCC) progressing after first-line platinum regimens…”
Get full text

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck by Ferris, Robert L, Blumenschein, George, Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Harrington, Kevin, Kasper, Stefan, Vokes, Everett E, Even, Caroline, Worden, Francis, Saba, Nabil F, Iglesias Docampo, Lara C, Haddad, Robert, Rordorf, Tamara, Kiyota, Naomi, Tahara, Makoto, Monga, Manish, Lynch, Mark, Geese, William J, Kopit, Justin, Shaw, James W, Gillison, Maura L

“…Patients with platinum-refractory head and neck cancer had significantly longer survival with nivolumab treatment than with standard, single-agent therapy…”
Get full text

Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes by Peyrade, Frédéric, Borel, Christian, Daste, Amaury, Even, Carolie, Saada-Bouzid, Esma, Guigay, Joël

“…Worldwide, head and neck carcinomas account for 5% of all malignancies. Two-thirds of patients relapse after initial multimodal therapy. Until early 2010, the…”
Get full text

Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial by Haddad, Robert, Concha‐Benavente, Fernando, Blumenschein, George, Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Kasper, Stefan, Vokes, Everett E., Worden, Francis, Saba, Nabil F., Tahara, Makoto, Jayaprakash, Vijayvel, Lynch, Mark, Li, Li, Gillison, Maura L., Harrington, Kevin J., Ferris, Robert L.

“…Background Response patterns with immune checkpoint inhibitors may be different from those with chemotherapy. Therefore, assessment of response to…”
Get full text

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort by Walter, T, Tougeron, D, Baudin, E, Le Malicot, K, Lecomte, T, Malka, D, Hentic, O, Manfredi, S, Bonnet, I, Guimbaud, R, Coriat, R, Lepère, C, Desauw, C, Thirot-Bidault, A, Dahan, L, Roquin, G, Aparicio, T, Legoux, J.-L, Lombard-Bohas, C, Scoazec, J.-Y, Lepage, C, Cadiot, G

“…Abstract Background Diagnosis and management of poorly differentiated gastro-entero-pancreatic (GEP) neuroendocrine carcinomas (NECs) remain challenging…”
Get full text

Treatment of inoperable elderly head and neck cancer patients by Guigay, Joël, Le Caer, Hervé, Ortholan, Cécile, Aupérin, Anne, Michel, Cécile, Mertens, Cécile

“…PURPOSE OF REVIEWElderly head and neck cancer (HNC) patients are very rarely enrolled in clinical trials, and even more so in dedicated trials in curative or…”
Get full text

Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome by Malouf, Gabriel G, Casiraghi, Odile, Deutsch, Eric, Guigay, Joel, Temam, Stéphane, Bourhis, Jean

“…Abstract Purpose Esthesioneuroblastomas, also called olfactory neuroblastomas (ENB) represent a rare sinonasal neurectodermal tumour which prognostic factors…”
Get full text

Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01 by MACHIELS, Jean-Pascal H, HENRY, Stéphanie, MOXHON, Anne, DUPREZ, Thierry, GUIGAY, Joel, ZANETTA, Sylvie, KAMINSKY, Marie-Christine, MICHOUX, Nicolas, ROMMEL, Denis, SCHMITZ, Sandra, BOMPAS, Emmanuelle, DILLIES, Anne-Françoise, FAIVRE, Sandrine

“…PURPOSE To assess the efficacy and toxicity of sunitinib monotherapy in palliative squamous cell carcinoma of the head and neck (SCCHN). PATIENTS AND METHODS…”
Get full text

Approach to the Patient with Recurrent/Metastatic Disease by Guigay, Joël, Sâada-Bouzid, Esma, Peyrade, Frédéric, Michel, Cécile

“…Opinion statement For most of patients with a recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), the treatment remains palliative: The…”
Get full text

Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer by Levy, Antonin, De Felice, Francesca, Bellefqih, Sara, Guigay, Joël, Deutsch, Eric, Nguyen, France, Blanchard, Pierre, Tao, Yungan

“…Background The purpose of this study was to evaluate the tolerability of concurrent radiotherapy and cetuximab (bioradiotherapy [BRT]) after taxane‐based…”
Get full text

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck by Ferris, Robert L., Blumenschein, George, Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Harrington, Kevin, Kasper, Stefan, Vokes, Everett E., Even, Caroline, Worden, Francis, Saba, Nabil F., Iglesias Docampo, Lara C., Haddad, Robert, Rordorf, Tamara, Kiyota, Naomi, Tahara, Makoto, Monga, Manish, Lynch, Mark, Geese, William J., Kopit, Justin, Shaw, James W., Gillison, Maura L.

Get full text

Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial by Guigay, Joël, Lee, Keun-Wook, Patel, Manish R, Daste, Amaury, Wong, Deborah J, Goel, Sanjay, Gordon, Michael S, Gutierrez, Martin, Balmanoukian, Ani, Le Tourneau, Christophe, Mita, Alain, Vansteene, Damien, Keilholz, Ulrich, Schöffski, Patrick, Grote, Hans Juergen, Zhou, Dongli, Bajars, Marcis, Penel, Nicolas

“…BackgroundRecurrent and/or metastatic (R/M) disease develops in approximately 65% of patients with squamous cell carcinoma of the head and neck (SCCHN) and is…”
Get full text

Systemic treatment and medical management of metastatic squamous cell carcinoma of the head and neck: Review of the literature and proposal for management changes by Peyrade, Frédéric, Cupissol, Didier, Geoffrois, Lionel, Rolland, Frédéric, Borel, Christian, Ciais, Catherine, Faivre, Sandrine, Guigay, Joël

“…Summary Objective Worldwide, head and neck carcinomas account for 5% of all malignancies. Two-thirds of patients relapse after initial multimodal therapy…”
Get full text

Consistent high concentration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients - evidence of non-exosomal transport by Gourzones, Claire, Ferrand, François-Régis, Amiel, Corinne, Vérillaud, Benjamin, Barat, Ana, Guérin, Maryse, Gattolliat, Charles-Henry, Gelin, Aurore, Klibi, Jihène, Chaaben, Arij Ben, Schneider, Véronique, Guemira, Fethi, Guigay, Joël, Lang, Philippe, Jimenez-Pailhes, Anne-Sophie, Busson, Pierre

“…BACKGROUND: Because latent Epstein Barr (EBV)-infection is a specific characteristic of malignant nasopharyngeal carcinoma (NPC), various molecules of viral…”
Get full text

Avelumab-cetuximab-radiotherapy (RT) versus standards of care (SoC) in locally advanced squamous cell carcinoma of the head and neck (SCCHN): Safety phase of the randomized trial GORTEC 2017-01 (REACH) by Tao, Yungan, Auperin, Anne, Sun, Xu Shan, Sire, Christian, Martin, Laurent, Bera, G, Coutte, Alexandre, Miroir, Jessica, Lafond, Cedrik, Colin-Batailhou, Natacha, Maillard, Aline, Gibel, Laurent, Michel, Cécile, Guigay, Joel, Bourhis, Jean

“…Abstract only…”
Get full text